US Patent Issued to Regeneron Pharmaceuticals on Sept. 15 for "Methods of treating an interleukin-2 receptor gamma-mediated disease or condition by administering an IL2 receptor gamma antibody" (New York Inventors)

ALEXANDRIA, Va., Sept. 15 -- United States Patent no. 12,735,496, issued on Sept. 15, was assigned to Regeneron Pharmaceuticals Inc. (Tarrytown, N.Y.).

"Methods of treating an interleukin-2 receptor gamma-mediated disease or condition by administering an IL2 receptor gamma antibody" was invented by Jamie M. Orengo (Cortlandt Manor, N.Y.) and Andrew J. Murphy (Croton-on-Hudson, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides antibodies and antigen-binding fragments (e.g., human antibodies) that bind specifically to human IL2 receptor gamma (IL2RGamma). Methods for treating or preventing diseases mediated by IL2RGamma (e.g., graft vs host disease) using the antibodies and fra...